Braidwell LP Boosts Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Braidwell LP grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 19.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,452,447 shares of the company's stock after purchasing an additional 557,934 shares during the period. Kiniksa Pharmaceuticals makes up approximately 2.0% of Braidwell LP's holdings, making the stock its 16th largest position. Braidwell LP owned approximately 4.78% of Kiniksa Pharmaceuticals worth $68,289,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Balyasny Asset Management L.P. bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth approximately $256,000. Bellevue Group AG bought a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $160,000. Bank of America Corp DE raised its holdings in Kiniksa Pharmaceuticals by 2.2% in the 4th quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock worth $4,268,000 after acquiring an additional 4,654 shares during the last quarter. Algert Global LLC lifted its position in Kiniksa Pharmaceuticals by 49.0% in the 4th quarter. Algert Global LLC now owns 135,814 shares of the company's stock valued at $2,686,000 after acquiring an additional 44,655 shares in the last quarter. Finally, PDT Partners LLC boosted its stake in Kiniksa Pharmaceuticals by 74.3% during the 4th quarter. PDT Partners LLC now owns 64,917 shares of the company's stock valued at $1,284,000 after purchasing an additional 27,675 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ross Moat sold 23,234 shares of Kiniksa Pharmaceuticals stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $28.02, for a total value of $651,016.68. Following the transaction, the insider now directly owns 9,415 shares in the company, valued at approximately $263,808.30. The trade was a 71.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 242,768 shares of company stock valued at $5,865,486. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ KNSA traded down $0.63 during midday trading on Friday, hitting $26.09. 272,058 shares of the company's stock traded hands, compared to its average volume of 480,646. The firm has a fifty day moving average of $22.40 and a 200 day moving average of $21.37. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $17.38 and a 1 year high of $28.56. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -186.34 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm's revenue was up 72.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.25) earnings per share. On average, equities analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KNSA. Wedbush reaffirmed an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Finally, Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.